EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
University of Trieste
Trieste, ItaliaPublicaciones en colaboración con investigadores/as de University of Trieste (6)
2024
-
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer
JNCI Cancer Spectrum, Vol. 8, Núm. 1
2021
-
Expected medium- And long-term impact of the COVID-19 outbreak in oncology
JCO Global Oncology, Vol. 7, pp. 162-172
2020
-
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population
Clinical and Translational Oncology, Vol. 22, Núm. 10, pp. 1857-1866
-
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
Breast Cancer Research and Treatment, Vol. 184, Núm. 2, pp. 421-431
-
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: A retrospective exploratory analysis of the BALLET study
European Journal of Cancer, Vol. 138, pp. S67
2016
-
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
Annals of Oncology, Vol. 27, Núm. 9, pp. 1719-1725